XFOR
X4 Pharmaceuticals Inc
NASDAQ: XFOR · HEALTHCARE · BIOTECHNOLOGY
$4.10
-0.49% today
Updated 2026-04-29
Market cap
$374.59M
P/E ratio
—
P/S ratio
10.67x
EPS (TTM)
$-1.87
Dividend yield
—
52W range
$1 – $5
Volume
0.5M
WallStSmart proprietary scores
33
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B5.0
Quality
C+2.0
Profitability
F6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$11.67
+184.63%
12-Month target
—
—
Intrinsic (DCF)
$30.14
Margin of safety
+88.62%
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 79.10% QoQ
+ 88.62% below intrinsic value
Risks
- Thin margins at -225.60%
- Negative free cash flow $-18.53M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $2.56M | $35.11M | $35.11M |
| Net income | $-93.87M | $-101.17M | $-37.45M | $-79.20M | $-23.93M |
| EPS | — | — | — | — | $-1.87 |
| Free cash flow | $-77.20M | $-96.57M | $-138.23M | $-88.62M | $-18.53M |
| Profit margin | — | — | -1,464.61% | -225.55% | -225.60% |
Peer comparison
Smart narrative
X4 Pharmaceuticals Inc trades at $4.10. Our Smart Value Score of 33/100 indicates the stock is weak. TTM revenue stands at $35.11M. with profit margins at -225.60%. Our DCF model estimates intrinsic value at $30.14.
Frequently asked questions
What is X4 Pharmaceuticals Inc's stock price?
X4 Pharmaceuticals Inc (XFOR) trades at $4.10.
Is X4 Pharmaceuticals Inc overvalued?
Smart Value Score 33/100 (Grade F, Strong Sell). DCF value $30.14.
What is the price target of X4 Pharmaceuticals Inc (XFOR)?
The analyst target price is $11.67, representing +184.6% upside from the current price of $4.10.
What is the intrinsic value of X4 Pharmaceuticals Inc (XFOR)?
Based on our DCF model, intrinsic value is $30.14, a +88.6% margin of safety versus $4.10.
What is X4 Pharmaceuticals Inc's revenue?
TTM revenue is $35.11M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.67x
ROE-76.00%
Beta0.33
50D MA$3.91
200D MA$3.46
Shares out0.09B
Float0.06B
Short ratio—
Avg volume0.5M
Performance
1 week+4.95%
1 month+12.77%
3 months+9.00%
YTD+6.00%
1 year—
3 years—
5 years—